Edgardo S. Santos, MD, FACP, discusses the current treatment landscape for patients with squamous cell carcinoma of the lung.
Edgardo S. Santos, MD
Advertisement
Articles by Edgardo S. Santos, MD
Expert panelists review considerations in the prophylactic treatment of chemotherapy-induced myelosuppression with special attention paid to unmet needs related to the use of G-CSF and ESAs.
Two leaders in the management of ES-SCLC provide an overview of chemotherapy-induced myelosuppression including key risk factors and its effect on patient outcomes.
Edgardo S. Santos, MD, discusses the potential role for CEACAM5- and KEAP1-targeted therapies in non–small cell lung cancer.
Edgardo S. Santos, MD, medical oncology, internal medicine, Boca Raton Regional Hospital, discusses exciting advancements in the field of lung cancer. Santos shared this insight during the 2016 OncLive State of the Science Summit on Lung Cancer.
Advertisement
Latest Updated Articles
Prophylactic Approaches to the Management of CIM in ES-SCLCPublished: July 8th 2022 | Updated:
Dr. Santos on Exciting Advancements in Field of Lung CancerPublished: November 22nd 2016 | Updated:
- An Overview of Chemotherapy-Induced Myelosuppression in ES-SCLC
Published: July 8th 2022 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5